Gastroesophageal Reflux Disease (GERD)

GERD is commonly divided by whether the esophageal lining is visibly damaged:

• Non-erosive reflux disease (NERD) — typical reflux symptoms without visible damage on endoscopy; the more common form, and the one in which amla’s positive trial was run.
• Erosive esophagitis — reflux that has caused visible inflammation and erosion of the esophageal lining, graded by severity at endoscopy.
• Barrett’s esophagus — a longer-term complication in which repeated acid exposure causes the lining to undergo metaplastic change, carrying a raised risk of esophageal adenocarcinoma. It is the main reason persistent GERD warrants proper follow-up.

Two related presentations sit alongside these. Laryngopharyngeal reflux produces throat rather than chest symptoms — hoarseness, throat clearing, a lump-in-the-throat sensation, chronic cough — and is often missed because heartburn may be absent entirely. Functional heartburn describes typical symptoms with normal acid exposure and no response to acid suppression; it is a pain-processing problem rather than an acid problem, and treating it with ever-stronger acid suppression does not work.

GERD arises when the lower esophageal sphincter — the muscular valve that normally seals the stomach off from the esophagus — becomes incompetent or relaxes at the wrong moments, allowing acidic stomach contents to reflux upward. Transient inappropriate relaxations of that sphincter, rather than uniformly low resting tone, account for most reflux events. A range of factors predispose to it: excess weight (particularly central adiposity, which raises intra-abdominal pressure), a hiatus hernia, delayed gastric emptying, pregnancy, smoking, alcohol, and medications that lower sphincter tone. Notably, menthol — found in peppermint and spearmint — relaxes the sphincter directly, a rare instance where an otherwise soothing carminative is precisely the wrong choice.

The classic symptom is heartburn: a burning sensation behind the breastbone that often rises into the throat and worsens on lying down or after meals. Other features include regurgitation of acid or food, a sour taste, difficulty swallowing, chronic cough, hoarseness, and a sensation of a lump in the throat. Prolonged, untreated reflux is what drives the metaplastic changes of Barrett’s esophagus.

The cancer risk is routinely overstated. A nationwide Danish cohort covering every Barrett’s patient in the country over 17 years found the annual risk of esophageal adenocarcinoma to be 0.12% — roughly a quarter of the 0.5% figure on which surveillance guidelines had been built ^{10Reference 10Hvid-Jensen et al. · 2011ObservationalIncidence of adenocarcinoma among patients with Barrett’s esophagus — nationwide population-based cohort studyView study →}. Barrett’s warrants follow-up, but for most people who have it, it is not a cancer sentence.

Uncomplicated heartburn is usually managed on symptoms alone, without any test. What changes that is a set of alarm features:

• Difficulty or pain on swallowing, or food sticking
• Unintended weight loss
• Vomiting blood, or black tarry stools
• Iron-deficiency anemia
• A first onset of significant reflux symptoms in later life
• Symptoms that persist despite adequate treatment

Any of these warrants prompt assessment and usually endoscopy. Reflux that has been present for years, particularly in the presence of other risk factors, is also the situation in which screening for Barrett’s is discussed. Esophageal adenocarcinoma and reflux produce overlapping symptoms early on, and demulcent herbs will comfortably mask both.

Proton pump inhibitors (omeprazole, esomeprazole, lansoprazole and relatives) are the most effective acid-suppressing drugs available and heal erosive esophagitis reliably. H2-receptor antagonists are weaker and faster-acting. Alginates — the raft-forming preparations — work mechanically rather than chemically, floating on the stomach contents to physically block reflux, which makes them useful for breakthrough and postprandial symptoms. Antireflux surgery is an option in well-selected patients with a mechanical problem.

Stopping a PPI can itself cause reflux symptoms, and this drives much of the interest in herbal alternatives. In a placebo-controlled trial, 44% of asymptomatic healthy volunteers developed acid-related symptoms — mainly heartburn and regurgitation — in the weeks after eight weeks of PPI treatment was withdrawn, through rebound acid hypersecretion ^{11Reference 11Reimer et al. · 2009RCTProton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy — randomised placebo-controlled trialView study →}. This is why people so often conclude they cannot stop, and why tapering rather than abruptly stopping, with an alginate or H2 blocker to cover the transition, is the sensible approach. It is a pharmacological rebound, not proof that the underlying disease has worsened — and it is a decision to make with the prescriber, not alone.

The lifestyle advice attached to reflux is a mixture of well-evidenced measures and inherited folklore. A systematic review assessing them against objective acid-exposure measurement found these hold up ^{12Reference 12Ness-Jensen et al. · 2016Systematic reviewLifestyle intervention in gastroesophageal reflux disease — systematic reviewView study →}:

• Weight loss, in those carrying excess weight, is the single best-supported intervention — randomized trials showed esophageal acid exposure time falling from 5.6% to 3.7% and from 8.0% to 5.5%.
• Stopping smoking reduced reflux symptoms in normal-weight individuals in a large prospective cohort.
• Elevating the head of the bed cut time with supine acid exposure from 21% to 15% versus lying flat — a large effect for a free intervention, and the right answer for night-time symptoms.
• Avoiding late evening meals measurably reduced supine acid exposure compared with eating earlier.

Blanket elimination of the traditional “trigger foods” — citrus, tomato, chocolate, coffee, fat, spice — has much weaker support than its cultural prominence suggests. Triggers are individual: worth identifying by observation, not worth eliminating wholesale on principle.

Reflux is the condition where general “digestive herb” advice most reliably backfires. Several of the most popular digestive botanicals are contraindicated or aggravating in reflux:

• Peppermint and spearmint. Menthol relaxes the lower esophageal sphincter — the exact mechanism of the disease. The standard carminative for indigestion is the wrong herb for reflux, and peppermint oil’s genuine value in irritable bowel syndrome does not transfer.
• Bitters, and gentian above all. The entire point of a digestive bitter is to increase gastric acid and bile secretion. Gentian is traditionally contraindicated in reflux and hyperacidity, alongside active peptic ulcer and biliary obstruction. The same logic applies to the bitter family generally.
• Ginger, artichoke, frankincense and cayenne. Heartburn and reflux are listed among the adverse effects of each, not the indications. Cayenne’s relationship with the gut is biphasic — low repeated doses may desensitize, high acute doses simply burn — and none of them has a reflux indication worth the risk.
• Even amla, the one reflux herb with a positive trial, is intensely sour and vitamin-C-rich, and it aggravates acidity in some people. Its rat data are biphasic too: gastroprotective at low doses, harmful at higher ones.

The general pattern is that the demulcents — the mucilaginous, coating herbs — are the rational botanical category for reflux, and the stimulating digestives are the category to avoid.

Supplements, nutrients and compounds used for gastroesophageal reflux disease (GERD).